Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Curr Issues Mol Biol ; 46(7): 7702-7718, 2024 Jul 19.
Article in English | MEDLINE | ID: mdl-39057097

ABSTRACT

The IgLON family of cell adhesion molecules consists of five members (LSAMP, OPCML, neurotrimin, NEGR1, and IgLON5) discovered as supporters of neuronal development, axon growth and guidance, and synapse formation and maintenance. Tumour suppression properties have recently been emerging based on antiproliferative effects through the modulation of oncogenic pathways. Available evidence endorses a role for non-coding RNAs or microRNAs as relevant controllers of IgLON molecule expression that can impact their critical physiological and pathological roles. Current findings support a function for long non-coding RNAs and microRNAs in the modulation of LSAMP expression in cell senescence, cancer biogenesis, addiction, and pulmonary hypertension. For OPCML, data point to a role for several microRNAs in the control of tumorigenesis. MicroRNAs were detected in neurotrimin-mediated functions in cancer biogenesis and in Schwann cell responses to peripheral nerve injury. For NEGR1, studies have mainly investigated microRNA involvement in neuronal responses to ischaemic injury, although data also exist about tumorigenesis and endothelial cell dysfunction. For IgLON5, information is only available about microRNA involved in myocardial infarction. In conclusion, despite much information being still missing and further research needed, the emerging picture favours a model in which non-coding RNAs exert a crucial role in modulating IgLON expression, ultimately affecting their important physiological functions.

2.
Psychiatry Clin Neurosci ; 77(3): 160-167, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36436204

ABSTRACT

INTRODUCTION: Impulse control disorders (e.g. pathological gambling, hypersexuality) may develop as adverse reactions to drugs. Pathogenetic hypotheses have mainly focused on D3-receptor agonism, and switching to alternatives with different pharmacologic mechanisms represents a common management strategy. Nonetheless, treatment failure is common and gaining pathophysiological insights is needed. AIM: We aimed to identify targets potentially contributing to pathologic impulsivity. METHOD: We performed a pharmacovigilance-pharmacodynamic study on dopamine agonists and antipsychotics using the Food and Drug Administration Adverse Event Reporting System (January 2004-December 2021). We estimated disproportionate reporting using the Bayesian information component. Using online public databases (IUPHAR, ChEMBL, PDSP, DrugBank), we calculated drug occupancies. To identify the targets potentially contributing to impulsivity, we fitted univariate regression models interpolating information components and occupancies within dopamine agonists and antipsychotics. Sensitivity analyses were performed to check for the robustness of the results. RESULTS: Among 19 887 reports of impulsivity, 5898 recorded an antipsychotic, and 3100 a dopamine agonist. The more robust signals concerned aripiprazole (N = 3091; median information component [95% confidence interval] = 4.51[4.45-4.55]) and brexpiprazole (229; 4.00[3.78-4.16]) for antipsychotics, pergolide (105; 5.82[5.50-6.06]) and pramipexole (2009; 5.43[5.36-5.48]) for dopamine agonists. Robust, significant positive associations between drug occupancy and impulsivity reporting were found for D3 within dopamine agonists (beta = 1.52; P-value = 0.047) and 5-HT1a within antipsychotics (1.92, 0.029). CONCLUSION: Our results supported the role of D3-receptor agonism in inducing impulsivity in dopamine receptor agonists and identified a potential role of 5-HT1a receptor agonism in antipsychotics. Investigating these receptors may drive towards a better management of drug-induced impulsivity.


Subject(s)
Antipsychotic Agents , Disruptive, Impulse Control, and Conduct Disorders , Humans , Dopamine Agonists/adverse effects , Antipsychotic Agents/adverse effects , Pharmacovigilance , Bayes Theorem , Disruptive, Impulse Control, and Conduct Disorders/chemically induced , Disruptive, Impulse Control, and Conduct Disorders/drug therapy
3.
Mol Pain ; 18: 17448069221087033, 2022.
Article in English | MEDLINE | ID: mdl-35255745

ABSTRACT

Fabry disease (FD) is a X-linked lysosomal storage disorder caused by deficient function of the alpha-galactosidase A (α-GalA) enzyme. α-GalA deficiency leads to multisystemic clinical manifestations caused by the preferential accumulation of globotriaosylceramide (Gb3). A hallmark symptom of FD patients is neuropathic pain that appears in the early stage of the disease as a result of peripheral small fiber damage. Previous studies have shown that Acetyl-L-carnitine (ALC) has neuroprotective, neurotrophic, and analgesic activity in animal models of neuropathic pain. To study the action of ALC on neuropathic pain associated with FD, we treated α-GalA gene null mice (α-GalA(-/0)) with ALC for 30 days. In α-Gal KO mice, ALC treatment induced acute and long-lasting analgesia, which persisted 1 month after drug withdrawal. This effect was antagonized by single administration of LY341495, an orthosteric antagonist of mGlu2/3 metabotropic glutamate receptors. We also found an up-regulation of mGlu2 receptors in cultured DRG neurons isolated from 30-day ALC-treated α-GalA KO mice. However, the up-regulation of mGlu2 receptors was no longer present in DRG neurons isolated 30 days after the end of treatment. Taken together, these findings suggest that ALC induces analgesia in an animal model of FD by up-regulating mGlu2 receptors, and that analgesia is maintained by additional mechanisms after ALC withdrawal. ALC might represent a valuable pharmacological strategy to reduce pain in FD patients.


Subject(s)
Analgesia , Fabry Disease , Neuralgia , Receptors, Metabotropic Glutamate , Acetylcarnitine/pharmacology , Animals , Fabry Disease/drug therapy , Fabry Disease/genetics , Fabry Disease/metabolism , Humans , Mice , Mice, Knockout , Neuralgia/drug therapy , Neuralgia/metabolism , Pain Management , Receptors, Metabotropic Glutamate/metabolism , alpha-Galactosidase/metabolism
4.
Int J Mol Sci ; 23(15)2022 Aug 05.
Article in English | MEDLINE | ID: mdl-35955854

ABSTRACT

CDKL5 deficiency disorder (CDD), a rare and severe neurodevelopmental disease caused by mutations in the X-linked CDKL5 gene, is characterized by early-onset epilepsy, intellectual disability, and autistic features. Although pharmacotherapy has shown promise in the CDD mouse model, safe and effective clinical treatments are still far off. Recently, we found increased microglial activation in the brain of a mouse model of CDD, the Cdkl5 KO mouse, suggesting that a neuroinflammatory state, known to be involved in brain maturation and neuronal dysfunctions, may contribute to the pathophysiology of CDD. The present study aims to evaluate the possible beneficial effect of treatment with luteolin, a natural flavonoid known to have anti-inflammatory and neuroprotective activities, on brain development and behavior in a heterozygous Cdkl5 (+/-) female mouse, the mouse model of CDD that best resembles the genetic clinical condition. We found that inhibition of neuroinflammation by chronic luteolin treatment ameliorates motor stereotypies, hyperactive profile and memory ability in Cdkl5 +/- mice. Luteolin treatment also increases hippocampal neurogenesis and improves dendritic spine maturation and dendritic arborization of hippocampal and cortical neurons. These findings show that microglia overactivation exerts a harmful action in the Cdkl5 +/- brain, suggesting that treatments aimed at counteracting the neuroinflammatory process should be considered as a promising adjuvant therapy for CDD.


Subject(s)
Luteolin , Protein Serine-Threonine Kinases , Animals , Brain , Disease Models, Animal , Epileptic Syndromes , Female , Luteolin/pharmacology , Luteolin/therapeutic use , Mice , Mice, Knockout , Protein Serine-Threonine Kinases/genetics , Spasms, Infantile
5.
Neurobiol Dis ; 153: 105304, 2021 06.
Article in English | MEDLINE | ID: mdl-33621640

ABSTRACT

CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a severe neurodevelopmental encephalopathy characterized by early-onset epilepsy and intellectual disability. Studies in mouse models have linked CDKL5 deficiency to defects in neuronal maturation and synaptic plasticity, and disruption of the excitatory/inhibitory balance. Interestingly, increased density of both GABAergic synaptic terminals and parvalbumin inhibitory interneurons was recently observed in the primary visual cortex of Cdkl5 knockout (KO) mice, suggesting that excessive GABAergic transmission might contribute to the visual deficits characteristic of CDD. However, the functional relevance of cortical GABAergic circuits abnormalities in these mutant mice has not been investigated so far. Here we examined GABAergic circuits in the perirhinal cortex (PRC) of Cdkl5 KO mice, where we previously observed impaired long-term potentiation (LTP) associated with deficits in novel object recognition (NOR) memory. We found a higher number of GABAergic (VGAT)-immunopositive terminals in the PRC of Cdkl5 KO compared to wild-type mice, suggesting that increased inhibitory transmission might contribute to LTP impairment. Interestingly, while exposure of PRC slices to the GABAA receptor antagonist picrotoxin had no positive effects on LTP in Cdkl5 KO mice, the selective GABAB receptor antagonist CGP55845 restored LTP magnitude, suggesting that exaggerated GABAB receptor-mediated inhibition contributes to LTP impairment in mutants. Moreover, acute in vivo treatment with CGP55845 increased the number of PSD95 positive puncta as well as density and maturation of dendritic spines in PRC, and restored NOR memory in Cdkl5 KO mice. The present data show the efficacy of limiting excessive GABAB receptor-mediated signaling in improving synaptic plasticity and cognition in CDD mice.


Subject(s)
Epileptic Syndromes/metabolism , GABA-B Receptor Antagonists/pharmacology , GABAergic Neurons/metabolism , Long-Term Potentiation/drug effects , Perirhinal Cortex/drug effects , Protein Serine-Threonine Kinases/genetics , Receptors, GABA-B/metabolism , Spasms, Infantile/metabolism , Animals , Disease Models, Animal , Epileptic Syndromes/genetics , GABA-A Receptor Antagonists/pharmacology , Long-Term Potentiation/genetics , Mice , Mice, Knockout , Neuronal Plasticity , Open Field Test , Perirhinal Cortex/metabolism , Phosphinic Acids/pharmacology , Picrotoxin/pharmacology , Propanolamines/pharmacology , Spasms, Infantile/genetics
6.
Hum Mol Genet ; 27(9): 1572-1592, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29474534

ABSTRACT

Cyclin-dependent kinase like-5 (CDKL5) disorder is a rare neurodevelopmental disease caused by mutations in the CDKL5 gene. The consequent misexpression of the CDKL5 protein in the nervous system leads to a severe phenotype characterized by intellectual disability, motor impairment, visual deficits and early-onset epilepsy. No therapy is available for CDKL5 disorder. It has been reported that a protein transduction domain (TAT) is able to deliver macromolecules into cells and even into the brain when fused to a given protein. We demonstrate that TAT-CDKL5 fusion protein is efficiently internalized by target cells and retains CDKL5 activity. Intracerebroventricular infusion of TAT-CDKL5 restored hippocampal development, hippocampus-dependent memory and breathing pattern in Cdkl5-null mice. Notably, systemically administered TAT-CDKL5 protein passed the blood-brain-barrier, reached the CNS, and rescued various neuroanatomical and behavioral defects, including breathing pattern and visual responses. Our results suggest that CDKL5 protein therapy may be an effective clinical tool for the treatment of CDKL5 disorder.


Subject(s)
Epileptic Syndromes/metabolism , Epileptic Syndromes/therapy , Protein Serine-Threonine Kinases/metabolism , Spasms, Infantile/metabolism , Spasms, Infantile/therapy , Animals , Brain , Hippocampus/metabolism , Hippocampus/pathology , Humans , Mice , Mice, Knockout , Neurons/metabolism , Neurons/pathology , Protein Serine-Threonine Kinases/genetics
7.
Int J Mol Sci ; 21(9)2020 May 11.
Article in English | MEDLINE | ID: mdl-32403292

ABSTRACT

Several chronic neuroinflammatory diseases, including Parkinson's disease (PD), have the so-called 'redox imbalance' in common, a dynamic system modulated by various factors. Among them, alteration of the mitochondrial functionality can cause overproduction of reactive oxygen species (ROS) with the consequent induction of oxidative DNA damage and apoptosis. Considering the failure of clinical trials with drugs that eliminate ROS directly, research currently focuses on approaches that counteract redox imbalance, thus restoring normal physiology in a neuroinflammatory condition. Herein, we used SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA), a neurotoxin broadly employed to generate experimental models of PD. Cells were pre-treated with the Rho-modulating Escherichia coli cytotoxic necrotizing factor 1 (CNF1), before the addition of 6-OHDA. Then, cell viability, mitochondrial morphology and dynamics, redox profile as well as autophagic markers expression were assessed. We found that CNF1 preserves cell viability and counteracts oxidative stress induced by 6-OHDA. These effects are accompanied by modulation of the mitochondrial network and an increase in macroautophagic markers. Our results confirm the Rho GTPases as suitable pharmacological targets to counteract neuroinflammatory diseases and evidence the potentiality of CNF1, whose beneficial effects on pathological animal models have been already proven to act against oxidative stress through an autophagic strategy.


Subject(s)
Antioxidants/pharmacology , Autophagy/drug effects , Bacterial Toxins/pharmacology , Escherichia coli Proteins/pharmacology , Oxidative Stress/drug effects , Oxidopamine/pharmacology , Animals , Apoptosis/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Neuroblastoma/metabolism , Neuroblastoma/pathology , Neuroprotective Agents/pharmacology , Reactive Oxygen Species/metabolism
8.
Hum Mol Genet ; 25(18): 3887-3907, 2016 09 15.
Article in English | MEDLINE | ID: mdl-27466189

ABSTRACT

Cyclin-dependent kinase-like 5 (CDKL5) is a Ser/Thr protein kinase predominantly expressed in the brain. Mutations of the CDKL5 gene lead to CDKL5 disorder, a neurodevelopmental pathology that shares several features with Rett Syndrome and is characterized by severe intellectual disability. The phosphorylation targets of CDKL5 are largely unknown, which hampers the discovery of therapeutic strategies for improving the neurological phenotype due to CDKL5 mutations. Here, we show that the histone deacetylase 4 (HDAC4) is a direct phosphorylation target of CDKL5 and that CDKL5-dependent phosphorylation promotes HDAC4 cytoplasmic retention. Nuclear HDAC4 binds to chromatin as well as to MEF2A transcription factor, leading to histone deacetylation and altered neuronal gene expression. By using a Cdkl5 knockout (Cdkl5 -/Y) mouse model, we found that hypophosphorylated HDAC4 translocates to the nucleus of neural precursor cells, thereby reducing histone 3 acetylation. This effect was reverted by re-expression of CDKL5 or by inhibition of HDAC4 activity through the HDAC4 inhibitor LMK235. In Cdkl5 -/Y mice treated with LMK235, defective survival and maturation of neuronal precursor cells and hippocampus-dependent memory were fully normalized. These results demonstrate a critical role of HDAC4 in the neurodevelopmental alterations due to CDKL5 mutations and suggest the possibility of HDAC4-targeted pharmacological interventions.


Subject(s)
Histone Deacetylases/biosynthesis , Intellectual Disability/genetics , Protein Serine-Threonine Kinases/genetics , Rett Syndrome/genetics , Spasms, Infantile/genetics , Animals , Disease Models, Animal , Enzyme Inhibitors/administration & dosage , Epileptic Syndromes , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Hippocampus/growth & development , Hippocampus/pathology , Histone Deacetylases/drug effects , Histone Deacetylases/genetics , Humans , Intellectual Disability/drug therapy , Intellectual Disability/physiopathology , MEF2 Transcription Factors/genetics , Mice , Mice, Knockout , Mutation , Neural Stem Cells/drug effects , Neurons/drug effects , Neurons/pathology , Phosphorylation , Rett Syndrome/drug therapy , Rett Syndrome/pathology , Spasms, Infantile/drug therapy , Spasms, Infantile/pathology
9.
Eur J Neurosci ; 47(9): 1054-1066, 2018 05.
Article in English | MEDLINE | ID: mdl-29603837

ABSTRACT

Cyclin-dependent kinase-like 5 (CDKL5) disorder is a severe neurodevelopmental disorder characterized by early-onset epileptic seizures, severe developmental delay, and intellectual disability. To date, no effective pharmacological treatments are available to improve the neurological phenotype that is due to mutations in the CDKL5 gene. Murine models of CDKL5 disorder have recently been generated, making the preclinical testing of pharmacological interventions possible. Using a Cdkl5 knockout (KO) mouse model, we recently demonstrated that deficiency of Cdkl5 causes defects in postnatal hippocampal development and hippocampus-dependent learning and memory. These defects were accompanied by an increased activity of GSK3ß, an important inhibitory regulator of many neuronal functions. Pharmacological inhibition of GSK3ß activity was able to recover hippocampal defects and cognitive performance in juvenile Cdkl5 KO mice, suggesting that GSK3ß inhibitors might be a potential therapeutic option for CDKL5 disorder. As GSK3ß inhibitors have been shown to have differential medication responses in young people and adults, this study was designed to examine whether GSK3ß is a possible therapeutic target both in juvenile and in adult CDKL5 patients. We found that treatment with the GSK3ß inhibitor Tideglusib during the juvenile period improved hippocampal development and hippocampus-dependent behaviors in Cdkl5 KO mice, while treatment later on in adulthood had no positive effects. These results suggest that pharmacological interventions aimed at normalizing impaired GSK3ß activity might have different age-dependent outcomes in CDKL5 disorder. This is of utmost importance in the development of therapeutic approaches in CDKL5 patients and in the design of rational clinical trials.


Subject(s)
Hippocampus/drug effects , Memory/drug effects , Neurons/drug effects , Thiadiazoles/pharmacology , Age Factors , Animals , Glycogen Synthase Kinase 3/metabolism , Mice, Knockout , Neurons/metabolism , Protein Serine-Threonine Kinases/genetics
10.
Neural Plast ; 2018: 9726950, 2018.
Article in English | MEDLINE | ID: mdl-29977282

ABSTRACT

CDKL5 disorder is a severe neurodevelopmental disorder caused by mutations in the X-linked CDKL5 (cyclin-dependent kinase-like five) gene. CDKL5 disorder primarily affects girls and is characterized by early-onset epileptic seizures, gross motor impairment, intellectual disability, and autistic features. Although all CDKL5 female patients are heterozygous, the most valid disease-related model, the heterozygous female Cdkl5 knockout (Cdkl5 +/-) mouse, has been little characterized. The lack of detailed behavioral profiling of this model remains a crucial gap that must be addressed in order to advance preclinical studies. Here, we provide a behavioral and molecular characterization of heterozygous Cdkl5 +/- mice. We found that Cdkl5 +/- mice reliably recapitulate several aspects of CDKL5 disorder, including autistic-like behaviors, defects in motor coordination and memory performance, and breathing abnormalities. These defects are associated with neuroanatomical alterations, such as reduced dendritic arborization and spine density of hippocampal neurons. Interestingly, Cdkl5 +/- mice show age-related alterations in protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) signaling, two crucial signaling pathways involved in many neurodevelopmental processes. In conclusion, our study provides a comprehensive overview of neurobehavioral phenotypes of heterozygous female Cdkl5 +/- mice and demonstrates that the heterozygous female might be a valuable animal model in preclinical studies on CDKL5 disorder.


Subject(s)
Brain/metabolism , Disease Models, Animal , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Rett Syndrome/genetics , Spasms, Infantile/genetics , Animals , Behavior, Animal , Epileptic Syndromes , Female , Heterozygote , Mice, Inbred C57BL , Mice, Knockout , Rett Syndrome/metabolism , Rett Syndrome/psychology , Signal Transduction , Spasms, Infantile/metabolism , Spasms, Infantile/psychology
11.
Mol Pain ; 122016.
Article in English | MEDLINE | ID: mdl-27531673

ABSTRACT

Fabry disease is a X-linked lysosomal storage disorder caused by deficient function of the alpha-galactosidase A (α-GalA) enzyme. α-GalA deficiency leads to multisystemic clinical manifestations caused by the preferential accumulation of globotriaosylceramide (Gb3) in the endothelium and vascular smooth muscles. A hallmark symptom of Fabry disease patients is neuropathic pain that appears in the early stage of the disease as a result of peripheral small fiber damage. The α-GalA gene null mouse model (α-GalA(-/0)) has provided molecular evidence for the molecular alterations in small type-C nociceptors in Fabry disease that may underlie their hyperexcitability, although the specific mechanism remains elusive. Here, we have addressed this question and report that small type-C nociceptors from α-GalA(-/0) mice exhibit a significant increase in the expression and function of the TRPV1 channel, a thermoTRP channel implicated in painful heat sensation. Notably, male α-GalA(-/0) mice displayed a ≈2-fold higher heat sensitivity than wild-type animals, consistent with the augmented expression levels and activity of TRPV1 in α-GalA(-/0) nociceptors. Intriguingly, blockade of neuronal exocytosis with peptide DD04107, a process that inhibits among others the algesic membrane recruitment of TRPV1 channels in peptidergic nociceptors, virtually eliminated the enhanced heat nociception of α-GalA(-/0) mice. Together, these findings suggest that the augmented expression of TRPV1 in α-GalA(-/0) nociceptors may underly at least in part their increased heat sensitivity, and imply that blockade of peripheral neuronal exocytosis may be a valuable pharmacological strategy to reduce pain in Fabry disease patients, increasing their quality of life.


Subject(s)
Fabry Disease/genetics , Pain/genetics , TRPV Cation Channels/metabolism , Animals , Disease Models, Animal , Exocytosis/physiology , Fabry Disease/metabolism , Female , Ganglia, Spinal/cytology , Mice, Transgenic , Neurons/metabolism , Nociception/physiology , TRPV Cation Channels/genetics , alpha-Galactosidase/genetics , alpha-Galactosidase/metabolism
12.
Neurobiol Dis ; 82: 298-310, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26143616

ABSTRACT

Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in a rare neurodevelopmental disorder characterized by early-onset seizures, severe developmental delay, intellectual disability and Rett syndrome-like features. CDKL5 is highly expressed in the brain during early postnatal stages, suggesting its importance for brain maturation. Using a newly-generated Cdkl5 knockout (Cdkl5 -/Y) mouse, we recently found that loss of Cdkl5 impairs postnatal hippocampal development with a reduction in neuronal precursor survival and maturation. These defects were accompanied by increased activity of the glycogen synthase kinase 3ß (GSK3ß) a crucial inhibitory regulator of many neurodevelopmental processes. The goal of the current study was to establish whether inhibition of GSK3ß corrects hippocampal developmental defects due to Cdkl5 loss. We found that treatment with the GSK3ß inhibitor SB216763 restored neuronal precursor survival, dendritic maturation, connectivity and hippocampus-dependent learning and memory in the Cdkl5 -/Y mouse. Importantly, these effects were retained one month after treatment cessation. At present, there are no therapeutic strategies to improve the neurological defects of subjects with CDKL5 disorder. Current results point at GSK3ß inhibitors as potential therapeutic tools for the improvement of abnormal brain development in CDKL5 disorder.


Subject(s)
Glycogen Synthase Kinase 3/antagonists & inhibitors , Hippocampus/drug effects , Indoles/pharmacology , Learning Disabilities/drug therapy , Maleimides/pharmacology , Neuroprotective Agents/pharmacology , Protein Serine-Threonine Kinases/deficiency , Animals , Apoptosis/drug effects , Apoptosis/physiology , Cell Survival/drug effects , Cell Survival/physiology , Disease Models, Animal , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Hippocampus/enzymology , Hippocampus/growth & development , Hippocampus/pathology , Learning Disabilities/enzymology , Learning Disabilities/pathology , Male , Maze Learning/drug effects , Maze Learning/physiology , Mice, Knockout , Neural Stem Cells/drug effects , Neural Stem Cells/enzymology , Neural Stem Cells/pathology , Neurogenesis/drug effects , Neurogenesis/physiology , Neurons/drug effects , Neurons/enzymology , Neurons/pathology , Nootropic Agents/pharmacology , Protein Kinase Inhibitors/pharmacology , Protein Serine-Threonine Kinases/genetics , Spatial Memory
13.
Neurobiol Dis ; 74: 204-18, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25497735

ABSTRACT

Individuals with Down syndrome (DS), a genetic condition caused by triplication of chromosome 21, are characterized by intellectual disability and are prone to develop Alzheimer's disease (AD), due to triplication of the amyloid precursor protein (APP) gene. Recent evidence in the Ts65Dn mouse model of DS shows that enhancement of serotonergic transmission with fluoxetine during the perinatal period rescues neurogenesis, dendritic pathology and behavior, indicating that cognitive impairment can be pharmacologically restored. A crucial question is whether the short-term effects of early treatments with fluoxetine disappear at adult life stages. In the current study we found that hippocampal neurogenesis, dendritic pathology and hippocampus/amygdala-dependent memory remained in their restored state when Ts65Dn mice, which had been neonatally treated with fluoxetine, reached adulthood. Additionally, we found that the increased levels of the APP-derived ßCTF peptide in adult Ts65Dn mice were normalized following neonatal treatment with fluoxetine. This effect was accompanied by restoration of endosomal abnormalities, a ßCTF-dependent feature of DS and AD. While untreated adult Ts65Dn mice had reduced hippocampal levels of the 5-HT1A receptor (5-HT1A-R) and methyl-CpG-binding protein (MeCP2), a protein that promotes 5-HT1A-R transcription, in neonatally-treated mice both 5-HT1A-R and MeCP2 were normalized. In view of the crucial role of serotonin in brain development, these findings suggest that the enduring outcome of neonatal treatment with fluoxetine may be due to MeCP2-dependent restoration of the 5-HT1A-R. Taken together, results provide new hope for the therapy of DS, showing that early treatment with fluoxetine enduringly restores cognitive impairment and prevents early signs of AD-like pathology.


Subject(s)
Alzheimer Disease/prevention & control , Cognition/drug effects , Down Syndrome/drug therapy , Fluoxetine/pharmacology , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Animals , Animals, Newborn , Cognition/physiology , Dendrites/drug effects , Dendrites/pathology , Dendrites/physiology , Disease Models, Animal , Down Syndrome/pathology , Down Syndrome/physiopathology , Down Syndrome/psychology , Endosomes/drug effects , Endosomes/pathology , Endosomes/physiology , Female , Hippocampus/drug effects , Hippocampus/pathology , Hippocampus/physiopathology , Male , Methyl-CpG-Binding Protein 2/metabolism , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Transgenic , Neural Stem Cells/drug effects , Neural Stem Cells/pathology , Neural Stem Cells/physiology , Neurogenesis/drug effects , Neurogenesis/physiology , Receptor, Serotonin, 5-HT1A/metabolism
14.
Clin Drug Investig ; 44(3): 141-148, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38294672

ABSTRACT

BACKGROUND AND OBJECTIVES: Long-term treatment of patients with rheumatoid arthritis with tumor necrosis factor-α inhibitors leads to initial changes in disease activity that can predict a late treatment response. This observational and retrospective study aimed to determine when it is possible to foresee the response to therapy in the case of long-standing rheumatoid arthritis comparing also the efficacy of the original biologics with their biosimilars. METHODS: A total of 1598 patients were recruited and treated with the original biologics, adalimumab and etanercept, or with biosimilars. Patients were monitored over a period of 48 months and disease activity scores (28-Joint Disease Activity Score, Simplified Disease Activity Index, and Clinical Disease Activity Index) were measured every 6 months. RESULTS: No differences in disease activity levels were observed in etanercept versus biosimilars (GP2015/SB4) and adalimumab versus biosimilar (GP2017) patient groups. All scores significantly decreased in all treatments during the first 18 months of therapy, and after 24 months reached a minimum that lasted up to 48 months. CONCLUSIONS: We conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor-α inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Biosimilar Pharmaceuticals , Humans , Etanercept/therapeutic use , Tumor Necrosis Factor-alpha , Adalimumab/therapeutic use , Tumor Necrosis Factor Inhibitors/therapeutic use , Retrospective Studies , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/drug therapy , Treatment Outcome , Infliximab
15.
Addict Biol ; 18(3): 425-33, 2013 May.
Article in English | MEDLINE | ID: mdl-21507157

ABSTRACT

Molecular mechanisms of adaptive transformations caused by alcohol exposure on opioid dynorphin and nociceptin systems have been investigated in the rat brain. Alcohol was intragastrically administered to rats to resemble human drinking with several hours of exposure: water or alcohol (20% in water) at a dose of 1.5 g/kg three times daily for 1 or 5 days. The development of tolerance and dependence were recorded daily. Brains were dissected 30 minutes (1- and 5-day groups) or 1, 3 or 7 days after the last administration for the three other 5-day groups (groups under withdrawal). Specific alterations in opioid genes expression were ascertained. In the amygdala, an up-regulation of prodynorphin and pronociceptin was observed in the 1-day group; moreover, pronociceptin and the kappa opioid receptor mRNAs in the 5-day group and both peptide precursors in the 1-day withdrawal group were also up-regulated. In the prefrontal cortex, an increase in prodynorhin expression in the 1-day group was detected. These data indicate a relevant role of the dynorphinergic system in the negative hedonic states associated with multiple alcohol exposure. The pattern of alterations observed for the nociceptin system appears to be consistent with its role of functional antagonism towards the actions of ethanol associated with other opioid peptides. Our findings could help to the understanding of how alcohol differentially affects the opioid systems in the brain and also suggest the dynorphin and nociceptin systems as possible targets for the treatment and/or prevention of alcohol dependence.


Subject(s)
Brain/drug effects , Central Nervous System Depressants/pharmacology , Dynorphins/genetics , Ethanol/pharmacology , Opioid Peptides/genetics , Alcohol Drinking/genetics , Alcohol Drinking/metabolism , Alcoholic Intoxication/genetics , Alcoholic Intoxication/metabolism , Amygdala/metabolism , Animals , Central Nervous System Depressants/blood , Dose-Response Relationship, Drug , Dynorphins/metabolism , Enkephalins/metabolism , Ethanol/blood , Gene Expression , Male , Opioid Peptides/metabolism , Protein Precursors/metabolism , Rats , Rats, Sprague-Dawley , Reflex, Righting/drug effects , Substance Withdrawal Syndrome/etiology , Nociceptin
16.
Genes (Basel) ; 14(10)2023 09 28.
Article in English | MEDLINE | ID: mdl-37895235

ABSTRACT

In the brain, cell adhesion molecules (CAMs) are critical for neurite outgrowth, axonal fasciculation, neuronal survival and migration, and synapse formation and maintenance. Among CAMs, the IgLON family comprises five members: Opioid Binding Protein/Cell Adhesion Molecule Like (OPCML or OBCAM), Limbic System Associated Membrane Protein (LSAMP), neurotrimin (NTM), Neuronal Growth Regulator 1 (NEGR1), and IgLON5. IgLONs exhibit three N-terminal C2 immunoglobulin domains; several glycosylation sites; and a glycosylphosphatidylinositol anchoring to the membrane. Interactions as homo- or heterodimers in cis and in trans, as well as binding to other molecules, appear critical for their functions. Shedding by metalloproteases generates soluble factors interacting with cellular receptors and activating signal transduction. The aim of this review was to analyse the available data implicating a role for IgLONs in neuropsychiatric disorders. Starting from the identification of a pathological role for antibodies against IgLON5 in an autoimmune neurodegenerative disease with a poorly understood mechanism of action, accumulating evidence links IgLONs to neuropsychiatric disorders, albeit with still undefined mechanisms which will require future thorough investigations.


Subject(s)
Neurodegenerative Diseases , Humans , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/metabolism , Neurons/metabolism , Cell Adhesion Molecules/metabolism , Immunoglobulins/genetics , Brain/metabolism , GPI-Linked Proteins/metabolism , Cell Adhesion Molecules, Neuronal/genetics
17.
Biomolecules ; 13(9)2023 09 15.
Article in English | MEDLINE | ID: mdl-37759796

ABSTRACT

Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a rare neurodevelopmental disease caused by mutations in the X-linked CDKL5 gene. CDD is characterized by a broad spectrum of clinical manifestations, including early-onset refractory epileptic seizures, intellectual disability, hypotonia, visual disturbances, and autism-like features. The Cdkl5 knockout (KO) mouse recapitulates several features of CDD, including autistic-like behavior, impaired learning and memory, and motor stereotypies. These behavioral alterations are accompanied by diminished neuronal maturation and survival, reduced dendritic branching and spine maturation, and marked microglia activation. There is currently no cure or effective treatment to ameliorate the symptoms of the disease. Aerobic exercise is known to exert multiple beneficial effects in the brain, not only by increasing neurogenesis, but also by improving motor and cognitive tasks. To date, no studies have analyzed the effect of physical exercise on the phenotype of a CDD mouse model. In view of the positive effects of voluntary running on the brain of mouse models of various human neurodevelopmental disorders, we sought to determine whether voluntary daily running, sustained over a month, could improve brain development and behavioral defects in Cdkl5 KO mice. Our study showed that long-term voluntary running improved the hyperlocomotion and impulsivity behaviors and memory performance of Cdkl5 KO mice. This is correlated with increased hippocampal neurogenesis, neuronal survival, spine maturation, and inhibition of microglia activation. These behavioral and structural improvements were associated with increased BDNF levels. Given the positive effects of BDNF on brain development and function, the present findings support the positive benefits of exercise as an adjuvant therapy for CDD.


Subject(s)
Motor Activity , Spasms, Infantile , Animals , Humans , Mice , Brain-Derived Neurotrophic Factor , Protein Serine-Threonine Kinases/genetics , Spasms, Infantile/therapy , Spasms, Infantile/drug therapy
18.
J Neurosci ; 30(15): 5311-25, 2010 Apr 14.
Article in English | MEDLINE | ID: mdl-20392953

ABSTRACT

alpha6* nicotinic acetylcholine receptors (nAChRs) are highly and selectively expressed by mesostriatal dopamine (DA) neurons. These neurons are thought to mediate several behavioral effects of nicotine, including locomotion, habit learning, and reinforcement. Yet the functional role of alpha6* nAChRs in midbrain DA neurons is mostly unknown. The aim of this study was to determine the composition and in vivo functional role of alpha6* nAChR in mesolimbic DA neurons of male rats. Immunoprecipitation and immunopurification techniques coupled with cell-specific lesions showed that the composition of alpha6* nAChR in the mesostriatal system is heterogeneous, with (non-alpha4)alpha6beta2* being predominant in the mesolimbic pathway and alpha4alpha6beta2* in the nigrostriatal pathway. We verified whether alpha6* receptors mediate the systemic effects of nicotine on the mesolimbic DA pathway by perfusing the selective antagonists alpha-conotoxin MII (CntxMII) (alpha3/alpha6beta2* selective) or alpha-conotoxin PIA (CntxPIA) (alpha6beta2* selective) into ventral tegmental area (VTA). The intra-VTA perfusion of CntxMII or CntxPIA markedly decreased systemic nicotine-elicited DA release in the nucleus accumbens and habituated locomotion; the intra-VTA perfusion of CntxMII also decreased the rate of nicotine infusion in the maintenance phase of nicotine, but not of food, self-administration. Overall, the results of these experiments show that the alpha6beta2* nAChRs expressed in the VTA are necessary for the effects of systemic nicotine on DA neuron activity and DA-dependent behaviors such as locomotion and reinforcement, and suggest that alpha6beta2*-selective compounds capable of crossing the blood-brain barrier may affect the addictive properties of nicotine and therefore be useful in the treatment of tobacco dependence.


Subject(s)
Nicotine/pharmacology , Nicotinic Agonists/pharmacology , Receptors, Nicotinic/metabolism , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/physiology , Animals , Conotoxins/pharmacology , Corpus Striatum/drug effects , Corpus Striatum/physiology , Dopamine/metabolism , Feeding Behavior/drug effects , Feeding Behavior/physiology , Male , Mesencephalon/drug effects , Mesencephalon/physiology , Motor Activity/drug effects , Motor Activity/physiology , Neural Pathways/physiology , Neurons/drug effects , Neurons/physiology , Nicotine/administration & dosage , Nicotinic Agonists/administration & dosage , Nicotinic Antagonists/pharmacology , Nucleus Accumbens/drug effects , Nucleus Accumbens/physiology , Rats , Rats, Sprague-Dawley , Reinforcement, Psychology , Self Administration
19.
Proc Natl Acad Sci U S A ; 105(40): 15570-5, 2008 Oct 07.
Article in English | MEDLINE | ID: mdl-18832146

ABSTRACT

New neurons in the adult dentate gyrus are widely held to incorporate into hippocampal circuitry via a stereotypical sequence of morphological and physiological transitions, yet the molecular control over this process remains unclear. We studied the role of brain-derived neurotrophic factor (BDNF)/TrkB signaling in adult neurogenesis by deleting the full-length TrkB via Cre expression within adult progenitors in TrkB(lox/lox) mice. By 4 weeks after deletion, the growth of dendrites and spines is reduced in adult-born neurons demonstrating that TrkB is required to create the basic organization of synaptic connections. Later, when new neurons normally display facilitated synaptic plasticity and become preferentially recruited into functional networks, lack of TrkB results in impaired neurogenesis-dependent long-term potentiation and cell survival becomes compromised. Because of the specific lack of TrkB signaling in recently generated neurons a remarkably increased anxiety-like behavior was observed in mice carrying the mutation, emphasizing the contribution of adult neurogenesis in regulating mood-related behavior.


Subject(s)
Anxiety/genetics , Hippocampus/physiology , Neurons/physiology , Receptor, trkB/genetics , Stem Cells/physiology , Animals , Anxiety/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Dendrites/metabolism , Dentate Gyrus/metabolism , Hippocampus/metabolism , Hippocampus/ultrastructure , Mice , Mice, Transgenic , Mutation , Neuronal Plasticity , Neurons/metabolism , Neurons/ultrastructure , Receptor, trkB/metabolism , Stem Cells/metabolism
20.
Methods Mol Biol ; 2201: 195-198, 2021.
Article in English | MEDLINE | ID: mdl-32975800

ABSTRACT

von Frey hairs are important tools for the study of mechanisms of cutaneous stimulation-induced sensory input. Mechanical force is exerted via application of a particular hair to the cutaneous receptive field until buckling of the hair occurs. The most commonly used von Frey filaments are productive in evaluating behavioral responses of neuropathic pain in preclinical and clinical research. To reduce the potential experimenter bias, automated instruments are being developed for behavioral assessment.


Subject(s)
Nociception/physiology , Pain Measurement/instrumentation , Pain Measurement/methods , Animals , Disease Models, Animal , Mice , Neuralgia , Nociceptive Pain/physiopathology , Nociceptors/metabolism , Pain Threshold/physiology , Physical Stimulation/instrumentation , Rats
SELECTION OF CITATIONS
SEARCH DETAIL